IMPLEMENTATION LEVEL

National

AFFECTED FLOW

Inflow

ANNOUNCED AS TEMPORARY

No

NON-TRADE-RELATED RATIONALE

No

ELIGIBLE FIRMS

all

JUMBO

No

TARIFF PEAK

No
← back to the state act
Inception date: 17 Feb 2011 | Removal date: open ended
Still in force

Instrument unclear

With Resolution of the Russian Government N 91 of 17 February 2011 was approved the Federal Programme titled 'Development of the Pharmaceutical and Medical Industry of the Russian Federation for the period up to 2020 and its farther perspective'. The purpose of the Programme is to finance and ensure the transition of the Russian pharmaceutical and medical industry to an innovative model of development. 
The overall financing of the programme from the federal budget is at the amount of 122.6 billion RUB (3.1 billion EUR). This figure is to be allocated in the period 2011--2020 among the following major categories:

  • Research and development works - 2.4 billion EUR.
  • Capital expenditure - 632 million EUR;
  • Other categories - 64 million EUR.

In addition to budgetary funds, the programme is expected to receive 1.6 billion EUR of investments from other sources.
 
The principal implementation measures related to the programme are divided into seven groups:

  • enhancement of the scientific and technological potential of the pharmaceutical industry;
  • enhancement of innovative potential of the pharmaceutical industry;
  • enhancement of scientific and technological potential of the medical industry;
  • enhancement of innovative potential of the medical industry;
  • investment in human capital, information infrastructure, modernisation, and other activities that stimulate the transition of the pharma and medical industries towards an innovation-based mode.

 
Some of the target indicators related to the programme are trade-related including: 

  • The volume of the locally produced medicines, including with the implementation of innovative technologies, to reach 734 billion RUB.
  • The share of the domestically produced medicines to reach 50%.
  • The share of the domestically produced strategic and life-saving medicines to reach 90% (see the attached related GTA measure Nr. 7687 for implementation).
  • The volume of domestically produced medical appliances and goods to reach 40%.
  • The export of pharmaceutical goods to reach 81 billion RUB.
  • The export of medical goods and appliances to reach 39.7 billion RUB.

The affected foreign jurisdictions are identified on the basis of the country of origin of the top foreign pharma companies that operate on the Russian market (see Annex 2 of the 2nd provided source for more details).
The GTA includes state guarantees and other financial incentives thatare likely to affect the restructuring and performance of firms facinginternational competition, whether from imports, in export markets, andfrom foreign subsidiaries.

AFFECTED COUNTRIES

MAP
TABLE
EXPORT

Please report this page in case you detect an inaccuracy in its content.